Clinical Observation of Miglitol Combined with Insulin in Newly Diagnosed Type 2 Diabetes Mellitus
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v2i3.469
Abstract
Objective — To study the clinical efficacy of miglitol combined with insulin in the treatment of newly diagnosed type 2 diabetes mellitus. Methods — 96 newly diagnosed type 2 diabetes patients admitted to our hospital from January 2021 to September 2021 were selected as the subjects of this study. They were randomly divided into two groups by drawing lots. The control group was treated with acarbose combined with insulin glargine, and the observation group was treated with miglitol combined with insulin glargine. Fasting blood glucose, 2h postprandial blood glucose, glycosylated hemoglobin (HbA1c), blood glucose compliance time, occurrence of adverse reactions and quality of life score of 2 groups were measured before and after treatment. Results — After treatment, fasting blood glucose, 2h postprandial blood glucose and HbA1c in both groups were lower than before (P < 0.05), and there was no statistical significance in the difference between the two groups and the time of blood glucose reaching the standard (P > 0.05). The incidence of adverse reactions in observation group was lower than that in control group, and the quality of life score in observation group was better than that in control group (P < 0.05). Conclusions — Miglitol or acarbose combined with insulin glargine can effectively control blood glucose in patients with newly diagnosed type 2 diabetes, but miglitol combined with insulin glargine has fewer adverse reactions, which can be used as the first choice for clinical treatment of newly diagnosed type 2 diabetes.
Keywords
miglitol, insulin glargine, type 2 diabetes mellitus, clinical curative effect
Full Text
PDF - Viewed/Downloaded: 20 TimesIndexation
Download Index RecordReferences
[2] Lulu Chen , Juan Zheng, Tianshu Zeng, et al. Analysis of insulin resistance phenotypes in patients with newly diagnosed type 2 diabetes mellitus [C]// 6th National Endocrinology Conference of Chinese Medical Association,2001.
[3] Hong Wei Gao , Hai Ning Wang, Tong Pei Hong, et al. Family history of type 2 diabetes is an independent risk factor for metabolic syndrome in individuals with normal glucose tolerance [J]. Chinese Journal of Diabetes, 2008(02):83-86.
[4] Huaxia Gan, Jiazhen Tang , Ji Brother Xu, et al. Efficacy and safety of insulin glargine in the treatment of type 2 diabetes mellitus [J]. Clinical Meta-J, 2008, 23(5):359-360.
[5] Yubo Wu , Huoliang Peng, Yaotang Wu , et al. Effect of repaglinide combined with insulin glargine in the treatment of type 2 diabetes mellitus [J]. Guangdong Medical Journal, 2011, 32(002):244-245.
[6] Xiaofang Zhai, Huiqin Li, Xiaofei Su, et al. Effect of insulin glargine on blood glucose control in patients with type 2 diabetes mellitus [J]. Chinese Journal of Diabetes, 2020, 28(04):38-41.
[7] Liyong Xing, Jingjing Zhang . Comparison of the efficacy of miglitol and acarbose combined with metformin in elderly patients with type 2 diabetes mellitus [J]. New world diabetes mellitus,2020,23(10):59-61.
[8] Feng Rui , Dun Zhang , Xueying Zhang , et al. Clinical observation of miglitol in the treatment of type 2 diabetes mellitus [J]. China Rural Health Service Management, 2021(2014-2):228-230.
[9] Xiaomin Li. Clinical study of miglitol combined with vigliptin in the treatment of type 2 diabetes [J]. China health and nutrition, 2020, 30(28):165-166.
[10] Tingyu Ke , Xueqin Niu, Juan Du, et al. Clinical observation of miglitol combined with insulin in the treatment of incipient type 2 diabetes mellitus [J]. Shandong Medicine, 2012, 052(017):84-85.
Copyright © 2021 Shengting Huang, Shiying Huang
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License